Leeward Investments LLC MA Sells 1,822 Shares of Cencora, Inc. (NYSE:COR)

Leeward Investments LLC MA trimmed its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 3.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,253 shares of the company's stock after selling 1,822 shares during the period. Leeward Investments LLC MA's holdings in Cencora were worth $14,531,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of COR. Hoey Investments Inc. bought a new stake in shares of Cencora in the 1st quarter worth approximately $28,000. Banque Transatlantique SA acquired a new stake in shares of Cencora during the fourth quarter valued at approximately $29,000. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora during the fourth quarter valued at approximately $30,000. Vermillion Wealth Management Inc. purchased a new position in Cencora during the fourth quarter valued at approximately $38,000. Finally, OFI Invest Asset Management purchased a new position in Cencora during the fourth quarter valued at approximately $41,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer directly owned 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,127 shares of company stock worth $9,812,296. 10.80% of the stock is owned by insiders.

Cencora Stock Performance

NYSE:COR traded up $6.20 during trading hours on Monday, hitting $302.43. 1,597,776 shares of the company traded hands, compared to its average volume of 1,507,152. The stock has a market capitalization of $58.62 billion, a price-to-earnings ratio of 35.08, a P/E/G ratio of 1.47 and a beta of 0.57. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The firm has a 50-day moving average of $291.12 and a 200 day moving average of $267.80. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the prior year, the company posted $3.80 EPS. The business's revenue was up 10.3% on a year-over-year basis. On average, analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.73%. The ex-dividend date was Friday, May 16th. Cencora's payout ratio is 25.52%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. UBS Group boosted their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Jefferies Financial Group boosted their target price on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research report on Monday, June 30th. Finally, Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $306.33.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.